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1. INTRODUCTION {#cam42925-sec-0005}
===============

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer after hepatocellular carcinoma. The incidence of ICC is increasing worldwide, with an average 2.3% annual increase.[1](#cam42925-bib-0001){ref-type="ref"}, [2](#cam42925-bib-0002){ref-type="ref"} The 5‐year survival rate for patients with ICC is less than 10%,[3](#cam42925-bib-0003){ref-type="ref"}, [4](#cam42925-bib-0004){ref-type="ref"} partly because approximately 80% of patients are diagnosed at a late stage when surgery is no longer a treatment option.[5](#cam42925-bib-0005){ref-type="ref"}, [6](#cam42925-bib-0006){ref-type="ref"} Currently, radical resection is the only potentially curative strategy for patients with ICC,[5](#cam42925-bib-0005){ref-type="ref"}, [6](#cam42925-bib-0006){ref-type="ref"} but the 5‐year survival rate even after radical resection is far from satisfactory. Hence, adjuvant therapy (AT) is badly warranted to improve the prognosis of ICC.

Recently, AT, such as transarterial chemoembolization (TACE), chemotherapy, radiotherapy, and comprehensive treatment, has been conducted prevalently worldwide to improve ICC patient prognosis after radical resection.[7](#cam42925-bib-0007){ref-type="ref"}, [8](#cam42925-bib-0008){ref-type="ref"}, [9](#cam42925-bib-0009){ref-type="ref"}, [10](#cam42925-bib-0010){ref-type="ref"}, [11](#cam42925-bib-0011){ref-type="ref"}, [12](#cam42925-bib-0012){ref-type="ref"}, [13](#cam42925-bib-0013){ref-type="ref"}, [14](#cam42925-bib-0014){ref-type="ref"} However, there is still controversy over whether ICC patients can benefit from AT after radical resection.[15](#cam42925-bib-0015){ref-type="ref"}, [16](#cam42925-bib-0016){ref-type="ref"}, [17](#cam42925-bib-0017){ref-type="ref"} The key is to identify those ICC patients who would benefit from AT, and exactly what form of AT is the most beneficial. Randomized controlled trials are hard to conduct due to the rare morbidity of ICC. Therefore, we conducted this retrospective multicenter study to identify those patients who benefited from AT.

2. MATERIAL AND METHODS {#cam42925-sec-0006}
=======================

2.1. Patient selection {#cam42925-sec-0007}
----------------------

This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by all 12 participating centers, including Mengchao hepatobiliary hospital, Eastern hepatobiliary surgery hospital, Affiliated Cancer Hospital of Chinese Academy of Medical Sciences, Tongji Hospital, Beijing Friendship Hospital, Xuanwu Hospital, Tiantan Hospital, affiliated Hospital of Chuanbei Medical University, Renji Hospital, West China Hospital, Southwest Hospital, and Second Hospital of Zhejiang University. Data, including baseline characteristics, operation parameters, and tumor characteristics, were collected via an electric case report form between December 2012 and December 2015.

2.2. Eligibility {#cam42925-sec-0008}
----------------

Patients were enrolled into this study if they: (a) had a confirmed histopathological diagnosis of ICC; (b) underwent an R0 resection with or without lymph node dissection (LND) and experienced no recurrence within 2 months of surgery; and (c) received postoperative AT, such as TACE, chemotherapy, radiotherapy, and comprehensive treatment, or not. Patients who met any of the following criteria were excluded from the study: (a) incomplete clinical data, (b) preoperative obstructive jaundice, (c) extrahepatic metastasis, (d) a positive margin, (e) mortality within 1 month of surgery, and (f) AT after recurrence.

2.3. Interventions {#cam42925-sec-0009}
------------------

A R0 resection was achieved by hepatectomy, with or without LND, albeit with slight procedural differences among different centers.

Those patients who underwent an R0 resection with no recurrence within 2 months of surgery were classed as having undergone a radical resection.

Following an assessment by a multidisciplinary team, patients underwent AT, such as TACE, chemotherapy, radiotherapy, and chemoradiotherapy, after radical resection, with the aim of reducing the risk of recurrence and improving prognosis.

One or two courses of TACE were conducted between 3 weeks and 2 months after resection. The most commonly used chemotherapeutic agents were 5‐fluorouracil (500 mg), epirubicin (20 mg), and hydroxycamptothecin (10 mg) with an emulsion of lipiodol (5‐10 mL). Adjuvant chemotherapy was often conducted within 1‐2 months following resection, and 4‐6 courses of fluoropyrimidine‐ or gemcitabine‐based chemotherapy regimens were used most frequently. Adjuvant radiotherapy was performed within 4‐8 weeks following resection, and intensity‐modulated radiation therapy with a total dose of 45‐50 Gy at 1.8‐2.0 Gy/fractions was the preferred option. Where a sequential chemoradiotherapy regimen was used, chemotherapy was often conducted after radiotherapy. Radiotherapy was targeted at the tumor bed with or without potential lymphatic drainage region.

2.4. Follow‐up and definition of endpoints {#cam42925-sec-0010}
------------------------------------------

All patients were periodically followed‐up every 2‐3 months in the first 2 years after resection, and then once every 6 months. Routine follow‐up tests included liver function tests, serum levels of carbohydrate antigen 199 (CA19‐9) and carcinoembryonic antigen (CEA), and an abdominal ultrasound. Contrast‐enhanced computed tomography or magnetic resonance imaging was only warranted once recurrence was clinically suspected. Recurrence or metastasis was defined as the appearance of new lesions with the same radiologic characteristics of ICC, and further treatment was started immediately whenever recurrence was confirmed.

The primary endpoint of this study was overall survival (OS), and the secondary endpoint was disease‐free survival (DFS). OS was calculated from the date of resection to either the date of death or the latest follow‐up. DFS was defined as from the time of resection to the time of recurrence (intrahepatic or extrahepatic) or the date of the latest follow‐up.

2.5. Propensity score matching {#cam42925-sec-0011}
------------------------------

Propensity score matching (PSM) was adopted to minimize selection bias, and the propensity score was determined using potential confounding factors. Patients were matched using a 1:2 ratio and the nearest neighbor method, with a caliper of 0.2.

2.6. Statistics {#cam42925-sec-0012}
---------------

Continuous variables were all re‐defined as categorical variables, hence, they were all evaluated using a Chi‐square test or Fisher\'s exact test between the two groups. Survival curves were determined by the Kaplan‐Meier method, both before and after PSM, and median OS and DFS were evaluated for the AT and non‐AT groups with hazard ratio (HR) and confidence interval (CI) 95%. A univariate analysis was used to identify prognostic factors of OS and DFS in ICC patients following radical resection, both before and after PSM. A multivariable Cox proportional hazards model of those prognostic factors with a *P* \< .2 was then executed to determine potential independent risk factors.

A subgroup analysis of the following variables was performed using the Kaplan‐Meier method to determine the OS of ICC patients receiving AT in the whole cohort; gender (female vs male), age (≤50 years vs \>50 years), hepatitis (no vs yes), CA19‐9 (≤37 U/mL vs \>37 U/mL), Child‐Pugh (grade A vs grade B), intraoperative blood loss (≤400 mL vs \>400 mL), tumor size (≤3 cm vs 3‐5 cm vs \>10 cm), tumor number (single vs multiple), surgical margin (\<1 cm vs ≥1 cm), differentiation (well‐moderate vs poor), satellite (no vs yes), microvascular invasion (MVI) (no vs yes), and lymph node metastasis (LNM) (no vs yes). A forest plot of the subgroup analysis was depicted with each estimated HR and 95% CI.

Patients from the AT and non‐AT groups were then subdivided into groups according to the 8th American Joint Committee on Cancer (AJCC) staging system and the established nomogram.[5](#cam42925-bib-0005){ref-type="ref"}, [11](#cam42925-bib-0011){ref-type="ref"} The median OS for each AT and non‐AT subgroups was then calculated using the Kaplan‐Meier method.

In addition, a subgroup analysis of different AT strategies was evaluated between the AT and non‐AT groups. Data analysis was conducted using Rstudio 3.6.1 software that included packages of "table1," "MatchIt," "survminer," "survival," "plyr," and "forestplot." A two‐tailed *P* \< .05 was considered statistically significant.

3. RESULTS {#cam42925-sec-0013}
==========

3.1. Baseline characteristics {#cam42925-sec-0014}
-----------------------------

Initially, 537 patients with ICC underwent resection, but 105 patients were excluded from the study for the following reasons; 18 patients (3.4%) for preoperative obstructive jaundice, three (0.5%) for ICC recurrence, 13 (2.4%) died within 1 month of resection, 54 (10.1%) for extrahepatic metastasis, and 17 (3.2%) for macrovascular invasion. Finally, 432 patients were enrolled in this study. During the median follow‐up of 22 months, 20 patients (4.6%) were not followed‐up, leaving 412 patients whose details were analyzed (Figure [1](#cam42925-fig-0001){ref-type="fig"}).

![Flow chart of patients\' enrollment](CAM4-9-2674-g001){#cam42925-fig-0001}

The baseline characteristics of the 412 patients analyzed in the study are shown in Table [1](#cam42925-tbl-0001){ref-type="table"}. The median patient age was 56 years, and 260 patients (63.1%) were male. The median size of the resected tumor was 6.5 cm, and 296 patients (71.8%) had a single tumor. In total, 109 patients (26.5%) underwent LND, among whom 53 patients (48.6%) were postoperatively confirmed as having LNM.

###### 

Clinicopathological characteristics before and after PSM

  Characteristics                               Before PSM     After PSM                                              
  --------------------------------------------- -------------- ------------- ------------ ------------- ------------- ------
  Gender                                                                                                              
  Female                                        127 (37.9%)    25 (32.5%)    .446         63 (40.9%)    25 (32.5%)    .271
  Male                                          208 (62.1%)    52 (67.5%)    91 (59.1%)   52 (67.5%)                  
  Age                                                                                                                 
  ≤50                                           94 (28.1%)     30 (39.0%)    .081         55 (35.7%)    30 (39.0%)    .736
  \>50                                          241 (71.9%)    47 (61.0%)    99 (64.3%)   47 (61.0%)                  
  HBV                                                                                                                 
  No                                            217 (64.8%)    49 (63.6%)    .955         98 (63.6%)    49 (63.6%)    1
  Yes                                           118 (35.20%)   28 (36.4%)    56 (36.4%)   28 (36.4%)                  
  CA19‐9 (U/mL)                                                                                                       
  ≤37                                           224 (66.9%)    49 (63.6%)    .684         99 (64.3%)    49 (63.6%)    1
  \>37                                          111 (33.1%)    28 (36.4%)    55 (35.7%)   28 (36.4%)                  
  Child‐Pugh                                                                                                          
  A                                             186 (55.5%)    52 (67.5%)    .073         93 (60.4%)    52 (67.5%)    .361
  B                                             149 (44.5%)    25 (32.5%)    61 (39.6%)   25 (32.5%)                  
  Blood loss (mL)                                                                                                     
  ≤400                                          242 (72.2%)    47 (61.0%)    .072         93 (60.4%)    47 (61.0%)    1
  \>400                                         93 (27.8%)     30 (39.0%)    61 (39.6%)   30 (39.0%)                  
  Margin                                                                                                              
  Wide                                          114 (34.0%)    35 (45.5%)    .080         64 (41.6%)    35 (45.5%)    .672
  Narrow                                        221 (66.0%)    42 (54.5%)    90 (58.4%)   42 (54.5%)                  
  Differentiation                                                                                                     
  Well and moderate                             265 (79.1%)    59 (76.6%)    .745         123 (79.9%)   59 (76.6%)    .690
  Poor                                          70 (20.9%)     18 (23.4%)    31 (20.1%)   18 (23.4%)                  
  Tumor size (cm)                                                                                                     
  ≤3                                            35 (10.4%)     10 (13.0%)    .064         28 (18.2%)    10 (13.0%)    .344
  3 \~ 5                                        83 (24.8%)     28 (36.4%)    43 (27.9%)   28 (36.4%)                  
  \>5                                           217 (64.8%     39 (50.6%)    83 (53.9%)   39 (50.6%)                  
  Tumor number                                                                                                        
  Single                                        237 (70.7%     59 (76.6%)    .372         120 (77.9%)   59 (76.6%)    .956
  Multiple                                      98 (29.3%)     18 (23.4%)    34 (22.1%)   18 (23.4%)                  
  Satellite                                                                                                           
  No                                            246 (73.4%     62 (80.5%)    .252         122 (79.2%)   62 (80.5%)    .954
  Yes                                           89 (26.6%)     15 (19.5%)    32 (20.8%)   15 (19.5%)                  
  MVI                                                                                                                 
  No                                            302 (90.1%     70 (90.9%)    1            146 (94.8%)   70 (90.9%)    .396
  Yes                                           33 (9.9%)      7 (9.1%)      8 (5.2%)     7 (9.1%)                    
  LNM                                                                                                                 
  No                                            295 (88.1%)    61 (79.2%)    .095         125 (81.2%)   61 (79.2%)    .860
  Yes                                           40 (11.9%)     16 (20.8%)    29 (18.8%)   16 (20.8%)                  
  AJCC[a](#cam42925-note-0003){ref-type="fn"}                                                                         
  I                                             198 (59.1%)    44 (57.1%)    .095         98 (63.6%)    44 (57.1%)    .604
  II                                            97 (29.0%)     17 (22.1%)    27 (17.5%)   17 (22.1%)                  
  III                                           40 (11.9%)     16 (20.8%)    29 (18.8%)   16 (20.8%)                  
  Nomogram                                                                                                            
  Mean (SD)                                     84.8 (209)     70.4 (63.9)   .290         99.4 (293)    70.4 (63.9)   .243

Abbreviations: AJCC, the American Joint Committee on Cancer; AT, adjuvant therapy; HBV, hepatitis B virus; LNM, lymph node metastasis; MVI, microvascular invasion; PSM, propensity score matching; SD, standard deviation.

According to the 8th edition AJCC staging guidelines.[5](#cam42925-bib-0005){ref-type="ref"}

John Wiley & Sons, Ltd

Of note, the clinicopathological characteristics of the AT and non‐AT groups were almost statistically comparable (Table [1](#cam42925-tbl-0001){ref-type="table"}), but, nonetheless, we conducted 1:2 PSM to decrease the potential for confounding factors (Table [2](#cam42925-tbl-0002){ref-type="table"}).

###### 

Univariate and multivariate analysis of overall survival and disease‐free survival for patients with intrahepatic cholangiocarcinoma in a whole cohort

  Characteristics                              OS                 DFS                                                                               
  -------------------------------------------- ------------------ -------- ------------------ ------ ------------------ -------- ------------------ ------
  Gender (female as ref)                                                                                                                            
  Male                                         1.36 (1.04‐1.77)   .023     1.48 (1.13‐1.93)   .004   1.32 (1.04‐1.66)   .02      1.42 (1.12‐1.79)   .004
  Age (≤50 y as ref)                                                                                                                                
  \>50 y                                       0.96 (0.74‐1.25)   .772                               0.91 (0.72‐1.15)   .435                         
  HBV (no as ref)                                                                                                                                   
  Yes                                          0.90 (0.70‐1.17)   .439                               0.84 (0.66‐1.06)   .139     0.95 (0.74‐1.21)   .672
  CA19‐9 (≤37 U/mL as ref)                                                                                                                          
  \>37 U/mL                                    1.28 (0.99‐1.66)   .062     1.38 (1.03‐1.85)   .030   1.13 (0.89‐1.43)   .310                         
  Child‐Pugh (A as ref)                                                                                                                             
  B                                            1.17 (0.92‐1.5)    .207                               1.17 (0.94‐1.46)   .159                         
  Blood loss (≤400 mL as ref)                                                                                                                       
  \>400 mL                                     0.98 (0.74‐1.29)   .878                               0.96 (0.75‐1.23)   .750                         
  Margin (wide ≥1 cm as ref)                                                                                                                        
  Narrow                                       1.44 (1.1‐1.88)    .008     1.35 (1.00‐1.83)   .053   1.42 (1.12‐1.80)   .004     1.14 (0.87‐1.49)   .333
  Differentiation (well and moderate as ref)                                                                                                        
  Poor                                         0.91 (0.67‐1.23)   .525                               0.78 (0.59‐1.03)   .085     0.89 (0.66‐1.21)   .459
  Tumor size (≤3 cm as ref)                                                                                                                         
  3 \~ 5 cm                                    1.60 (0.93‐2.73)   .089     1.54 (0.89‐2.64)   .122   1.29 (0.83‐2.00)   .250     1.24 (0.79‐1.93)   .344
  \>5 cm                                       2.61 (1.59‐4.31)   \<.001   2.27 (1.37‐3.77)   .002   2.03 (1.36‐3.04)   .001     1.80 (1.18‐2.74)   .006
  Tumor number (single as ref)                                                                                                                      
  Multiple                                     1.84 (1.41‐2.4)    \<.001   0.97 (0.59‐1.58)   .898   1.84 (1.44‐2.35)   \<.001   1.12 (0.72‐1.72)   .614
  Satellite (no as ref)                                                                                                                             
  Yes                                          2.20 (1.68‐2.88)   \<.001   1.86 (1.14‐3.03)   .013   2.14 (1.67‐2.74)   \<.001   1.65 (1.06‐2.56)   .026
  MVI (no as ref)                                                                                                                                   
  Yes                                          1.71 (1.16‐2.52)   .007     1.49 (0.99‐2.23)   .054   1.36 (0.94‐1.96)   .104     1.29 (0.88‐1.88)   .197
  LNM (no as ref)                                                                                                                                   
  Yes                                          2.00 (1.42‐2.83)   .001     1.82 (1.25‐2.63)   .002   1.60 (1.17‐2.2)    .003     1.61 (1.15‐2.25)   .005
  Postoperative AT (no as ref)                                                                                                                      
  Yes                                          0.63 (0.44‐0.92)   .015     0.70 (0.48‐1.03)   .068   0.73 (0.53‐0.99)   .045     0.80 (0.58‐1.11)   .177

Abbreviations: AT, adjuvant therapy; CI, confidence interval; DFS, disease‐free survival; HBV, hepatitis B virus; HR, hazard ratio; LNM, lymph node metastasis; MVI, microvascular invasion; OS, overall survival.

John Wiley & Sons, Ltd

3.2. Long‐term outcomes {#cam42925-sec-0015}
-----------------------

The median OS was longer in the AT than in the non‐AT group (43.0 months vs 21.0 months, *P* = .015; Figure [2](#cam42925-fig-0002){ref-type="fig"}A). The 1‐, 3‐, and 5‐year OS rates were also significantly higher in the AT group than in the non‐AT group (74% vs 63%, 50% vs 31%, 43% vs 24%, all *P* \< .05, respectively). The median DFS time was longer in the AT than in the non‐AT group (16.0 months vs 11.0 months, *P* = .045; Figure [2](#cam42925-fig-0002){ref-type="fig"}B). The 1‐, 3‐, and 5‐year DFS rates were also significantly higher in the AT group than in the non‐AT group (56% vs 46%, 36% vs 20%, 24% vs 14%, all *P* \< .05, respectively).

![Overall survival (OS) (A) and disease‐free survival (DFS) (B) of patients receiving adjuvant therapy (AT) or not in a whole cohort. OS (C) and DFS (D) of patients receiving AT or not after 1:2 propensity score matching](CAM4-9-2674-g002){#cam42925-fig-0002}

After 1:2 PSM, the median OS time was still longer in the AT than in the non‐AT group (37.0 months vs 21.0 months, *P* = .023; Figure [2](#cam42925-fig-0002){ref-type="fig"}C), and the 1‐, 3‐, and 5‐year OS rates were still significantly higher in the AT group than in the non‐AT group (74% vs 63%, 52% vs 27%, 42% vs 20%, all *P* \< .05, respectively). Similarly, after 1:2 PSM, the median DFS time was still longer in the AT than in the non‐AT group (16.0 months vs 11.0 months, *P* = .046; Figure [2](#cam42925-fig-0002){ref-type="fig"}D), and the 1‐, 3‐, and 5‐year DFS rates were still significantly higher in the AT than in the non‐AT group (58% vs 45%, 35% vs 19%, 24% vs 13%, all *P* \< .05, respectively).

3.3. Univariate and multivariate analyses of prognostic factors for OS and DFS in ICC patients following radical resection {#cam42925-sec-0016}
--------------------------------------------------------------------------------------------------------------------------

A univariate analysis of the whole patient cohort identified gender, margin, tumor size, tumor number, satellite, LNM, and AT as prognostic factors for OS (all *P* \< .05; Table [2](#cam42925-tbl-0002){ref-type="table"}). A subsequent multivariate analysis showed that being male (*P* = .004, HR: 1.48, 95% CI: 1.13‐1.93), a CA19‐9 \>37 U/mL (*P* = .03, HR: 1.38, 95% CI: 1.03‐1.85), tumor size \>5 cm (*P* = .002, HR: 2.27, 95% CI: 1.37‐3.77), satellite (*P* = .013, HR: 1.86, 95% CI: 1.14‐3.03), and LNM (*P* = .002, HR: 1.82, 95% CI: 1.25‐2.63) were all independent risk factors for OS (Table [2](#cam42925-tbl-0002){ref-type="table"}).

A univariate analysis of variables for DFS identified gender, margin, tumor size, tumor number, satellite, LNM, and AT as prognostic factors (all *P* \< .05; Table [2](#cam42925-tbl-0002){ref-type="table"}). A multivariate analysis showed that gender (*P* = .004, HR: 1.42, 95% CI: 1.12‐1.79), tumor size (*P* = .006, HR: 1.80, 95% CI: 1.18‐2.74), satellite (*P* = .026, HR: 1.65, 95% CI: 1.06‐2.65), and LNM (*P* = .005, HR: 1.61, 95% CI: 1.15‐2.25) were all independent risk factors for DFS (Table [2](#cam42925-tbl-0002){ref-type="table"}).

3.4. Subgroup analysis stratified by risk factors {#cam42925-sec-0017}
-------------------------------------------------

Subgroup analysis showed that patients with the following characteristics benefited from AT in terms of OS: age ≤50 years, CA19‐9 ≤37 U/mL, Child‐Pugh grading B, intraoperative blood loss \>400 mL, well‐moderate tumor differentiation, and multiple tumors or no MVI (HR: 0.47, 95% CI: 0.25‐0.89, *P* = .02; HR = 0.52, 95% CI: 0.32‐0.85, *P* = .009; HR = 0.46, 95% CI: 0.24‐0.88, *P* = .019; HR = 0.42, 95% CI: 0.21‐0.86, *P* = .017; HR = 0.57, 95% CI: 0.37‐0.88, *P* = .011; HR = 0.42, 95% CI: 0.19‐0.91, *P* = .029; and HR = 0.62, 95% CI: 0.42‐0.92, *P* = .016, respectively; Figure [3](#cam42925-fig-0003){ref-type="fig"}).

![Forest plot of subgroup analysis stratified by risk factors](CAM4-9-2674-g003){#cam42925-fig-0003}

3.5. Subgroup analysis based on established staging systems {#cam42925-sec-0018}
-----------------------------------------------------------

Patients included in the study were divided into three subgroups according to the 8th AJCC staging system.[5](#cam42925-bib-0005){ref-type="ref"} In total, 242 (58.74%), 114 (27.67%), and 56 (13.59%) patients were in the stage Ⅰ, stage Ⅱ, and stage Ⅲ subgroups, respectively. Good prognostic stratification was observed among the three subgroups (*P* \< .05; Figure [S1](#cam42925-sup-0001){ref-type="supplementary-material"}A). However, the use of AT failed to improve the OS for patients at stage Ⅰ, Ⅱ, or Ⅲ (43.0 months vs 30.0 months, *P* = .21, Figure [4](#cam42925-fig-0004){ref-type="fig"}A; NA vs 15.0 months, *P* = .081, Figure [4](#cam42925-fig-0004){ref-type="fig"}B; 17.0 months vs 8.0 months, *P* = .099, Figure [4](#cam42925-fig-0004){ref-type="fig"}C, respectively).

![Overall survival (OS) of patients with stage Ⅰ (A), stage Ⅱ (B), and stage Ⅲ (C) according to the 8th AJCC stage system receiving adjuvant therapy (AT) or not. OS of patients with "low‐risk" (D), "middle‐risk" (E), and "high‐risk" (F) according to the established nomogram](CAM4-9-2674-g004){#cam42925-fig-0004}

According to the established nomogram,[11](#cam42925-bib-0011){ref-type="ref"} patients were divided into three risk subgroups. In total, 62 (15%), 288 (70%), and 62 (15%) patients were grouped into the "low‐risk," "middle‐risk," and "high‐risk" subgroups, all of which exhibited good prognostic stratification (*P* \< .05; Figure [S1](#cam42925-sup-0001){ref-type="supplementary-material"}B). The use of AT failed to improve OS for either "low‐risk" or "high‐risk" patients (63.0 months vs 28.0 months, *P* = .73, Figure [4](#cam42925-fig-0004){ref-type="fig"}D; 17.0 months vs 14.0 months, *P* = .23, Figure [4](#cam42925-fig-0004){ref-type="fig"}F, respectively). However, patients in the "middle‐risk" subgroup who received AT had a longer median OS (43.0 months vs 20.0 months, *P* = .033; Figure [4](#cam42925-fig-0004){ref-type="fig"}E).

3.6. Subgroup analysis stratified by different AT strategies {#cam42925-sec-0019}
------------------------------------------------------------

In total, 77 patients (18.9%) received AT after surgery before recurrence, including 32 (7.8%) patients who received adjuvant TACE, 21 (5.1%) patients who received adjuvant chemotherapy, 10 (2.4%) patients who received adjuvant radiotherapy, and 14 (3.4%) patients who received adjuvant chemoradiotherapy. Compared to the OS of non‐AT patients, the median OS in the adjuvant TACE, chemotherapy, radiotherapy, and chemoradiotherapy groups was as follows: 63.0 months vs 21.0 months (*P* = .11; Figure [5](#cam42925-fig-0005){ref-type="fig"}A), 37.0 months vs 21.0 months (*P* = .039; Figure [5](#cam42925-fig-0005){ref-type="fig"}A), 36.0 months vs 21.0 months (*P* = .63; Figure [5](#cam42925-fig-0005){ref-type="fig"}A), and 17.0 months vs 21.0 months (*P* = .48; Figure [5](#cam42925-fig-0005){ref-type="fig"}A), respectively. While the corresponding median DFS rates for each group were 8.0 months vs 10.0 months (*P* = .007; Figure [5](#cam42925-fig-0005){ref-type="fig"}B), 12.0 months vs 10.0 months (*P* = .22; Figure [5](#cam42925-fig-0005){ref-type="fig"}B), 4.0 months vs 10.0 months (*P* = .50; Figure [5](#cam42925-fig-0005){ref-type="fig"}B), and 5.0 months vs 10.0 months (*P* = .80; Figure [5](#cam42925-fig-0005){ref-type="fig"}B), respectively.

![Overall survival (OS) (A) and disease‐free survival (DFS) (B) of patients receiving adjuvant TACE, chemotherapy, radiotherapy, and chemoradiotherapy, compared with those without adjuvant therapy](CAM4-9-2674-g005){#cam42925-fig-0005}

4. DISCUSSION {#cam42925-sec-0020}
=============

Various AT strategies have been used in ICC patients following radical resection to improve their prognosis; however, the benefit of AT has always been questioned.[18](#cam42925-bib-0018){ref-type="ref"}, [19](#cam42925-bib-0019){ref-type="ref"}, [20](#cam42925-bib-0020){ref-type="ref"}, [21](#cam42925-bib-0021){ref-type="ref"}, [22](#cam42925-bib-0022){ref-type="ref"}, [23](#cam42925-bib-0023){ref-type="ref"} In this study, we collected multicenter ICC patient data, including 77 patients who received AT after a radical resection, and the results showed that these patients had a longer median OS and DFS than who did not receive AT. These results were also confirmed after 1:2 PSM. Hence, AT should be recommended for patients with ICC, following radical resection. However, this did not indicate whether one group of ICC patients was more likely to benefit from AT than another, or which AT strategy was the most effective.

In a real‐world scenario, "high‐risk" patients are much more likely to receive AT following resection; however, the efficacy of AT varies among patients. When evaluating any clinical strategy, survival is the most convincing indicator of efficacy. Therefore, we performed risk factor subgroup analyses to determine the characteristics of ICC patients most likely to benefit from AT in terms of OS. The results showed that patients with the following characteristics could significantly benefit from undergoing AT: age ≤50 years, CA19‐9 ≤37 U/mL, Child‐Pugh grading B, intraoperative blood loss \>400 mL, well‐moderate differentiation, multiple tumors, no satellite, or no MVI (all *P* \< .05). However, this list of characteristics is confusing since being aged ≤50 years, having a CA19‐9 level ≤37 U/mL, well‐moderate tumor differentiation, and the presence of no satellites and MVI are often considered to be "protective factors" of OS, while a Child‐Pugh grading B and the presence of multiple tumors are "risk factors." Hence, it is imperative to identify an appropriate staging system for the successful postoperative management of ICC patients.

The AJCC cancer staging system is the most widely used staging system to predict the prognosis of ICC worldwide. In this study, patients were divided into three groups according to the 8th AJCC cancer staging system for ICC, each with distinct OS differences[5](#cam42925-bib-0005){ref-type="ref"} (*P* \< .05). However, this failed to confirm the benefit of AT in any of the subgroups. It has been reported that a prognostic nomogram based on prognostic factors, with corresponding weights based on their survival impact, is better than conventional staging systems for predicting patient prognosis.[11](#cam42925-bib-0011){ref-type="ref"} Therefore, we also divided patients into "low‐risk," "middle‐risk," and "high‐risk" subgroups, each with distinctly different survival rates (*P* \< .05). We found that only "middle‐risk" patients benefited from receiving AT. This indicates that the established nomogram is superior to the AJCC cancer staging system in the postoperative management of ICC and that "middle‐risk" patients should be strongly recommended to receive AT following radical resection.

The incidence of ICC patients receiving adjuvant chemotherapy is reported to be as high as 46.6%,[10](#cam42925-bib-0010){ref-type="ref"} although cholangiocarcinoma is less sensitive to chemotherapeutics than other cancers.[18](#cam42925-bib-0018){ref-type="ref"}, [24](#cam42925-bib-0024){ref-type="ref"} Fluoropyrimidine‐ and gemcitabine‐based chemotherapy regimens are widely used[20](#cam42925-bib-0020){ref-type="ref"}, [25](#cam42925-bib-0025){ref-type="ref"} and were confirmed to prolong OS in recent meta‐analyses.[16](#cam42925-bib-0016){ref-type="ref"}, [17](#cam42925-bib-0017){ref-type="ref"} In this study, we also found that adjuvant chemotherapy could prolong the median OS, which is in accordance with the findings of previous reports.[19](#cam42925-bib-0019){ref-type="ref"}, [20](#cam42925-bib-0020){ref-type="ref"}

TACE is often used to manage ICC in unresectable patients,[26](#cam42925-bib-0026){ref-type="ref"}, [27](#cam42925-bib-0027){ref-type="ref"} but more recently, adjuvant TACE has also been administered to reduce ICC recurrence.[7](#cam42925-bib-0007){ref-type="ref"}, [21](#cam42925-bib-0021){ref-type="ref"}, [23](#cam42925-bib-0023){ref-type="ref"} Previous studies have found that adjuvant TACE can improve ICC patient prognosis following resection, mainly by reducing the rate of recurrence. However, this has been questioned by Shen et al.[28](#cam42925-bib-0028){ref-type="ref"} In our opinion, adjuvant TACE might reduce the risk of recurrence when cancerous cells are carried in the blood, but it is insufficient in cases where they are spread through the lymph system.[29](#cam42925-bib-0029){ref-type="ref"}, [30](#cam42925-bib-0030){ref-type="ref"} In this study, we found that adjuvant TACE prolonged the median DFS but failed to prolong the median OS, which is consistent with our hypothesis. In future, an adjuvant combination therapy of chemotherapy and TACE should be trialed in a clinical setting.

Radiotherapy plays an increasingly important role in the management of ICC.[31](#cam42925-bib-0031){ref-type="ref"}, [32](#cam42925-bib-0032){ref-type="ref"} However, adjuvant radiotherapy has been found to be inefficient in improving the prognosis of ICC patients following R0 resection,[31](#cam42925-bib-0031){ref-type="ref"}, [32](#cam42925-bib-0032){ref-type="ref"} which was confirmed by this study. Data from the Taiwan Cancer Registry database found that more patients (53.4%) received adjuvant chemoradiotherapy following resection than radiotherapy alone following resection, and that concurrent rather than sequential chemoradiotherapy improved survival in patients at an advanced stage or with a positive margin.[10](#cam42925-bib-0010){ref-type="ref"} In this study, only 14 (3.4%) patients received adjuvant chemoradiotherapy, most of whom underwent sequential chemoradiotherapy, and our results showed that adjuvant chemoradiotherapy improved neither the OS nor the DFS. However, more trials should be conducted to identify the efficacy of adjuvant chemoradiotherapy in cases of ICC, especially with the advent of stereotactic body radiotherapy.

However, there were several limitations to this study. Firstly, this was a retrospective study and, although we conducted PSM, both selection and recall bias were hard to avoid. Secondly, adverse events related to AT were not evaluated, although no cases of mortality were detected. Finally, only 77 patients (18.9%) underwent AT, and therefore, our subgroup analysis was of limited significance. Hence, the AT resulting in the best survival should be explored further.

5. CONCLUSION {#cam42925-sec-0021}
=============

With the current data, we conclude that AT should be recommended in the management of ICC following radical resection, especially for those "middle‐risk" patients, as evaluated by the established nomogram. However, prospective trials are needed to determine the most beneficial AT strategy.
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